Rishi R. Goel,Mark M. Painter,Sokratis A. Apostolidis,Divij Mathew,Wenzhao Meng,Aaron M. Rosenfeld,Kendall A. Lundgreen,Arnold Reynaldi,David S. Khoury,Ajinkya Pattekar,Sigrid Gouma,Leticia Kuri-Cervantes,Philip Hicks,Sarah Dysinger,Amanda Hicks,Harsh Sharma,Sarah Herring,Scott Korte,Amy E. Baxter,Derek A. Oldridge,Josephine R. Giles,Madison E. Weirick,Christopher M. McAllister,Moses Awofolaju,Nicole Tanenbaum,Elizabeth M. Drapeau,Jeanette Dougherty,Sherea Long,Kurt D’Andrea,Jacob T. Hamilton,Maura McLaughlin,Justine C. Williams,Sharon Adamski,Oliva Kuthuru,Ian Frank,Michael R. Betts,Laura A. Vella,Alba Grifoni,Daniela Weiskopf,Alessandro Sette,Scott E. Hensley,Miles P. Davenport,Paul Bates,Eline T. Luning Prak,Allison R. Greenplate,E. John Wherry,

Abstract:ABSTRACT SARS-CoV-2 mRNA vaccines have shown remarkable efficacy, especially in preventing severe illness and hospitalization. However, the emergence of several variants of concern and reports of declining antibody levels have raised uncertainty about the durability of immune memory following vaccination. In this study, we longitudinally profiled both antibody and cellular immune responses in SARS-CoV-2 naïve and recovered individuals from pre-vaccine baseline to 6 months post-mRNA vaccination. Antibody and neutralizing titers decayed from peak levels but remained detectable in all subjects at 6 months post-vaccination. Functional memory B cell responses, including those specific for the receptor binding domain (RBD) of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants, were also efficiently generated by mRNA vaccination and continued to increase in frequency between 3 and 6 months post-vaccination. Notably, most memory B cells induced by mRNA vaccines were capable of cross-binding variants of concern, and B cell receptor sequencing revealed significantly more hypermutation in these RBD variant-binding clones compared to clones that exclusively bound wild-type RBD. Moreover, the percent of variant cross-binding memory B cells was higher in vaccinees than individuals who recovered from mild COVID-19. mRNA vaccination also generated antigen-specific CD8+ T cells and durable memory CD4+ T cells in most individuals, with early CD4+ T cell responses correlating with humoral immunity at later timepoints. These findings demonstrate robust, multi-component humoral and cellular immune memory to SARS-CoV-2 and current variants of concern for at least 6 months after mRNA vaccination. Finally, we observed that boosting of pre-existing immunity with mRNA vaccination in SARS-CoV-2 recovered individuals primarily increased antibody responses in the short-term without significantly altering antibody decay rates or long-term B and T cell memory. Together, this study provides insights into the generation and evolution of vaccine-induced immunity to SARS-CoV-2, including variants of concern, and has implications for future booster strategies. GRAPHICAL ABSTRACT

Early human B cell signatures of the primary antibody response to mRNA vaccination

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination

mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Magnitude and Durability of the Antibody Response to mRNA-Based Vaccination Among SARS-CoV-2 Seronegative and Seropositive Health Care Personnel

B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies

Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

Evolution of antibody immunity to SARS-CoV-2

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination – kinetics of plasma antibodies, plasmablasts and memory B cells

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses

Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Characterization of a heterogenous activated B cell compartment arising early after antigen exposure preceding long-lived memory B cell formation

Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection